PREDICT Cytomegalovirus (CMV)

CompletedOBSERVATIONAL
Enrollment

84

Participants

Timeline

Start Date

October 31, 2017

Primary Completion Date

November 25, 2019

Study Completion Date

November 25, 2019

Conditions
Lung Transplant
Interventions
OTHER

Procedure

Serial blood draws. Participants will be enrolled either pre-transplant or within 45 days post-transplant and will be followed over the course of 18 months post transplant. Protocol mandated serial measurement of cytomegalovirus (CMV)-specific immune signature will occur pre-transplant (as applicable) and at post-transplant timepoint months 2, -3, -6, -9, -12 and -18.

Trial Locations (4)

21287

Johns Hopkins Hospital: Transplantation, Baltimore

27710

Duke University Medical Center: Transplantation, Durham

44195

Cleveland Clinic Foundation: Transplantation, Cleveland

M5G 2C4

Toronto General Hospital: Transplantation, Toronto

All Listed Sponsors
collaborator

Clinical Trials in Organ Transplantation

NETWORK

collaborator

Rho Federal Systems Division, Inc.

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03300882 - PREDICT Cytomegalovirus (CMV) | Biotech Hunter | Biotech Hunter